Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Basal Cell 7Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 3Keratosis, Actinic 3Cholangiocarcinoma 3Tongue Neoplasms 2Pleural Diseases 2Non-Muscle Invasive Bladder Neoplasms 2Mycosis Fungoides 2Mesothelioma, Malignant 2Carcinoma, Transitional Cell 2Bile Duct Neoplasms 2Basal Cell Nevus Syndrome 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomatitis 1Skin Neoplasms 1Sezary Syndrome 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Photosensitivity Disorders 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pain 1Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoid Interstitial Pneumonia 1Lung Neoplasms 1

Interventions

pembrolizumab 189Cisplatin 47Paclitaxel 45Carboplatin 44lenvatinib 31Docetaxel 23Pemetrexed 21Fluorouracil 20Capecitabine 17Gemcitabine 15Oxaliplatin 14Saline Solution 13Albumin-Bound Paclitaxel 11130-nm albumin-bound paclitaxel 10epacadostat 9Leucovorin 9Cetuximab 9olaparib 7Irinotecan 7Bevacizumab 7Etoposide 6enzalutamide 5durvalumab 5belzutifan 5Nivolumab 5Dexamethasone 5Surgical Procedures, Operative 4Radiotherapy 4trifluridine tipiracil drug combination 3spartalizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × 1-phenyl-3,3-dimethyltriazene × Clear all
NCT05386056 2022-11-28

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Peking University

Phase 2 Unknown
54 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡